ACROBiosystems

ACROBiosystems

Newark, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $65M

Overview

ACROBiosystems is a specialized reagent provider serving the global research and diagnostic markets. The company leverages expertise in protein engineering and production to supply critical tools for drug discovery, assay development, and diagnostic manufacturing. Its position in Germany provides access to a strong European biotech ecosystem, while its global reach suggests a focus on serving international customers. As a supplier to the industry, its success is tied to the overall growth in biomedical R&D spending.

Antibodies

Technology Platform

Advanced recombinant protein expression and purification using mammalian, insect, and bacterial host systems, with expertise in protein conjugation and characterization.

Funding History

2
Total raised:$65M
Series B$50M
Series A$15M

Opportunities

The company is positioned to capitalize on the global growth in biologics R&D and diagnostic development, which drives demand for high-quality protein tools.
Expanding its custom development and manufacturing organization (CDMO) services, particularly for GMP-grade materials, represents a significant high-margin growth opportunity.

Risk Factors

Intense competition in the reagent market could pressure prices and margins.
Geopolitical and supply chain complexities arising from its operational footprint across Europe and Asia pose operational and intellectual property risks.

Competitive Landscape

ACROBiosystems competes in a crowded global market for research reagents against large, diversified players like Thermo Fisher Scientific (through brands like Invitrogen) and Abcam, as well as specialized recombinant protein providers such as Sino Biological and R&D Systems (Bio-Techne). Its differentiation hinges on product quality, data depth, and its hybrid geographic operational model.